A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.

摘要: Alisporivir is a cyclophilin inhibitor with demonstrated in vitro and vivo activity against hepatitis C 11 virus (HCV). We estimated antiviral effectiveness of alisporivir alone or combination 12 pegylated-Inteferon (peg-IFN) 88 patients infected different HCV genotypes treated for four 13 weeks. The pharmacokinetics both drugs were modeled used as driving functions the viral 14 kinetic model. Genotype was found to significantly affect (e= 86.3% 15 99.1% genotype-1/4 genotype-2/3, respectively, p<10 -7) cells loss rate (δ= 16 0.22 vs 0.39 day -1 -6). 17 not across genotype high doses ≥600 mg QD. simulated 18 virologic responses other dosing regimens genotype-2/3 using 19 Our predictions consistently matched observed responses, demonstrating that this model 20 could be useful tool anticipating response optimize alisporivir-based therapies.